Griseofulvin compound and pharmaceutical use thereof
US-11993593-B2 · May 28, 2024 · US
Therapeutic agent and treatment method for ameliorating uremia
US9783518B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9783518-B2 |
| Application number | US-98842306-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 7, 2006 |
| Priority date | Jul 8, 2005 |
| Publication date | Oct 10, 2017 |
| Grant date | Oct 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin I 2 derivative having a specific structure, such as beraprost sodium. The therapeutic agent for uremia ameliorates the uremia concurred in patients with chronic renal failure without accompanying side effects, and restoration of decreased appetite, improvements in activities, increase in body weight and the like are achieved. The therapeutic effect of uremia is clear alleviation or disappearance of symptoms of uremia grasped as clinical symptoms, observed in the state of renal failure, especially even in spite of the state wherein the decrease in renal function is progressed.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of ameliorating symptoms of uremia comprising administering a therapeutic agent comprising beraprost or each isomer constituting beraprost, or a salt thereof as an effective ingredient to an animal belonging to the Family Felidae, wherein an effective dosage is a dosage that does not statistically significantly lower blood pressure. 2. The method according to claim 1 , wherein the dose per administration is not more than 10…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K31/343Primary
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9783518B2 cover?
- A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin I 2 derivative having a specific structure, …
- Who is the assignee on this patent?
- Takenaka Masahiko, Yamane Yoshihisa, Ida Nobutaka, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/343. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).